Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on February 21, 2025. The filing reports the entry into a new material definitive agreement regarding the sale of common stock and the termination of a prior sales agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on capital market activities.
Material Changes
- Termination of Prior Agreement: The Company terminated its Sales Agreement with Cowen and Company, LLC, effective February 14, 2025. Sales of common stock under the previous prospectus supplement were suspended on February 4, 2025.
- New ATM Agreement: On February 21, 2025, the Company entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
- Offering Capacity: Under the new agreement, the Company may offer and sell shares of Common Stock with an aggregate offering price of up to $75.0 million.
- Compensation: The Company will pay Wainwright a commission of 3.0% of the aggregate gross proceeds from each sale, plus reimbursement for certain legal fees.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or management commentary on business performance. The Company is not obligated to sell any shares under the new ATM Agreement. Sales are discretionary and subject to market conditions. The agreement may be terminated by the Company with five business days' prior written notice or by Wainwright at any time.
Investor Verification Checklist
- Verify the current share price and trading volume on the Nasdaq Capital Market to assess the potential dilution impact of a $75.0 million offering.
- Review the Company's most recent 10-K or 10-Q filings to understand current cash reserves and liquidity needs driving this capital raise.
- Confirm the status of the shelf registration statement (File No. 333-270459) referenced in the filing.
- Monitor future 8-K filings for actual sales executed under the new ATM Agreement.